|Application ||WB, E|
|Other Accession||Q8N0V4, 32469737|
|Reactivity||Human, Mouse, Rat|
|Calculated MW||63006 Da|
|Application Notes||LGI2 antibody can be used for the detection of LGI2 by Western blot at 1 - 2 µg/mL.|
|Target/Specificity||Lgi2; This LGI2 antibody is predicted to be specific to LGI2 and not recognize other LGI proteins. Three isoforms of LGI2 are known to exist; this LGI2 antibody will recognize only the longest.|
|Reconstitution & Storage||LGI2 antibody can be stored at 4℃ for three months and -20℃, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.|
|Precautions||LGI2 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
LGI2 Antibody: The leucine-rich, glioma inactivated gene 2 (LGI2) is a member of the LGI family in which LGI1 is the exemplar. The LGI family consists of four of highly related proteins containing leucine-rich repeats (LRRs) which are highly similar to other transmembrane signaling molecules and receptors. LGI1 has been identified as a candidate tumor suppressor gene for glioma and plays a role in autodominant lateral temporal epilepsy (ADTLE), an epileptic syndrome characterized by focal seizures with predominant auditory symptoms. Despite its high homology with LGI1 and similar pattern of expression, mutations in LGI2 have not been found to be associated with ADTLE.
Gu W, Gibert Y, Wirth T, et al. Using gene-history and expression analysis to assess the involvement of LGI genes in human disorders. Mol. Biol. Evol.2005; 22:2209-16.
Chernova OB, Somerville RP and Cowell JK. A novel gene, LGI1, from 10q24 is rearranged and downregulated in malignant brain tumors. Oncogene1998; 17:2873-81.
Berkovic SF, Izzillo P, McMahon JM, et al. LGI1 mutations in temporal lobe epilepsies. Neurology2004; 62:1115-9.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.